Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Parallel-Group Comparative Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Subcutaneous Injection of TAK-850 in Healthy Adult Subjects

NCT02313155 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02313155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02313155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Parallel-Group Comparative Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Subcutaneous Injection of TAK-850 in Healthy Adult Subjects
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2014
Completion date
January 31, 2015
Enrollment
110 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

influenza infection